Rhythm Pharmaceuticals highlights IMCIVREE launch progress in acquired hypothalamic obesity presentation
Reuters2026/09/08 22:22- Rhythm Pharmaceuticals highlighted IMCIVREE’s U.S. launch for acquired hypothalamic obesity following FDA clearance on March 19, 2026.
- Japan launch anticipated by year-end 2026; European country launches expected to begin in 2027 following European Commission authorization.
- Early U.S. uptake: more than 400 patient start forms in the first 14 weeks; about 300 unique prescribers.
- Cash, cash equivalents, short-term investments totaled USD 330.9 million as of June 30, 2026; 68.6 million common shares outstanding.
- Pipeline milestones include a year-end 2026 start of a pivotal Phase 3 trial of oral bivamelagon in acquired hypothalamic obesity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stellar network stablecoin transfer volume increases by 50%, supply decreases by 11.7%
The U.S. Treasury market remains overheated! Besent expands repo program, emphasizing "this is not quantitative easing"
U.S. Treasury Secretary Janet Yellen stated on Tuesday that the Treasury's decision last month to expand the buyback program for older-dated U.S. Treasury bonds was mainly aimed at "cooling down" the bond market, which has been heating up recently, and helping the market return to a more balanced state.
Lupatech ratifies Mipel’s BRL 1.59 million private commercial note issuance
Crypto prices
More
